breast cancer

The Side-Out Foundation Logo

Side-Out Protocol Phase 1 Results

June 21, 2013 — There is nothing necessarily unique about presenting a cancer trial at a national oncology conference, but when that trial is funded by high school and college athletes, it becomes extraordinary. At the American Society of Clinical Oncology (ASCO) Annual Meeting in early June, scientists introduced the results for the Side-Out Protocol, […]

Side-Out Protocol Phase 1 Results Read More »

New Research on Inflammatory Breast Cancer

Recently, Emanuel Petriocoin and Lance Liotta of George Mason University’s (GMU) Center for Applied Proteomics & Molecular Medicine (CAPMM) discovered that activation of the protein ALK (anaplastic lymphoma kinase) is associated with inflammatory breast cancer, a particularly aggressive form of the disease: “Mason Research Gives Hope to Women With Deadliest Breast Cancer”. Although this study

New Research on Inflammatory Breast Cancer Read More »

Side-Out Foundation Awards $160K to the FNIH

Rick Dunetz presents the check to FNIH (from left to right: David Wholley (director, The Biomarkers Consortium, FNIH), Dr. Scott Campbell (executive director and CEO, FNIH), Rick Dunetz (founder and executive director, Side-Out), Dr. Emanuel (Chip) Petricoin (co-director, GMU Center for Applied Proteomics and Molecular Medicine) and Bryant Dunetz (Rick’s dad and COO, Side-Out)) From

Side-Out Foundation Awards $160K to the FNIH Read More »

Advocating for the Breast Cancer Deadline!

About three weeks ago, several of us at Side-Out attended The National Breast Cancer Coalition’s (NBCC) Annual Advocacy Training Conference in Washington, DC (Saturday, April 30th through Tuesday, May 3rd). If you haven’t heard about it yet, NBCC set a deadline for the end of breast cancer. In a document explaining the deadline, the organization

Advocating for the Breast Cancer Deadline! Read More »

Side-Out Protocol: Year One

Fairfax, VA — March 29, 2011 — The Side-Out Foundation is funding a study looking at a novel approach in treating patients living with advanced breast cancer. This clinical trial (SO-BCA-001) is laying the groundwork for biologically based treatments for breast cancer, utilizing molecular profiling of the patient’s tumor tissue to find potential targets and

Side-Out Protocol: Year One Read More »